100 likes | 103 Vues
Phase 3. Treatment Experienced. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE Treatment Experienced (TE). Source: Kwo P, et al. Gastroenterology. 2017;152:164-75. Elbasvir-Grazoprevir + /- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE Study: Features.
E N D
Phase 3 TreatmentExperienced Elbasvir-Grazoprevir+/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE Treatment Experienced (TE) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir+/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE Study: Features Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Study Design 0 12 16 24 28 36 Week n =105 SVR12 GT1, 4 or 6 Prior Treatment (n = 420) EBR-GRZ SVR12 n =104 EBR-GRZ + RBV n =105 SVR12 EBR-GRZ n =106 SVR12 EBR-GRZ + RBV Abbreviations: EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin Drug DosingElbasvir-grazoprevir (50/100 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 800 to 1400 mg/day N =14 Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Baseline Characteristics Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Results C-EDGE TE: SVR 12*, by Genotype 356/370 32/36 4/4 * Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Results C-EDGE TE: SVR 12* by Regimen and Treatment Duration (GT 1, 4, or 6) 97/105 98/104 97/105 104/106 12-Week Regimen 16-Week Regimen * Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Results C-EDGE TE: SVR 12 by Regimen, Treatment Duration, and GT1 Subtype 55/60 34/34 56/60 28/29 45/48 46/47 55/55 37/37 12-Week Regimen 16-Week Regimen Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Results C-EDGE TE: SVR 12 in Patients with Baseline NS5A RAVs 6/10 4/4 6/9 4/5 3/6 11/12 6/6 9/9 12-Week Regimen 16-Week Regimen Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6C-EDGE TE: Results Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.